Intellia Therapeutics grants Marantz stock and options

The option grant's first 33% vests on October 26, 2027, followed by 24 monthly installments for the remaining 67%.

Rhea-AI Filing Summary

Intellia Therapeutics, Inc. (NTLA) reported that Jing L. Marantz, EVP, Chief Medical Officer, received 199,822 restricted stock units, each representing a contingent right to receive one common share, and options covering 275,061 common shares on October 26, 2026. The options have an $11.26 exercise price and expire October 25, 2036.

Insider Trade Summary

Grant/Award: 474,883 shares

Grant/Award 2 txns

Insider Marantz Jing L.

Role EVP, Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F2	275,061	$0.00	$0.00
Grant/Award	Common Stock F1	199,822	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 275,061 contracts (Direct); Common Stock — 199,822 shares (Direct)

Footnotes (2)

1. F1. Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
2. F2. This option was granted on October 26, 2026 with respect to shares of Common Stock, with 33% vesting on October 26, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

Key Figures

Restricted stock units: 199,822 units Options granted: 275,061 options Exercise price: $11.26 per share +4 more

7 metrics

Restricted stock units 199,822 units Granted October 26, 2026; each represents a contingent right to receive one common share.

Options granted 275,061 options Granted October 26, 2026, covering common shares.

Exercise price $11.26 per share Options granted October 26, 2026.

Initial option vesting 33% Vests October 26, 2027.

Remaining option vesting 67% Vests in 24 substantially equal monthly installments thereafter.

Option vesting installments 24 installments For the remaining 67% of the option grant.

Option expiration date October 25, 2036 Options granted October 26, 2026.

Key Terms

restricted stock units, contingent right, vesting, substantially equal monthly installments

4 terms

restricted stock units financial

"grant of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"representing a contingent right to receive one share"

vesting financial

"with 33% vesting on October 26, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

substantially equal monthly installments financial

"24 substantially equal monthly installments thereafter"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What awards did NTLA's chief medical officer receive?

Jing L. Marantz, Intellia Therapeutics' EVP, Chief Medical Officer, received 199,822 restricted stock units and options covering 275,061 common shares on October 26, 2026. Each restricted stock unit represents a contingent right to receive one common share; the options have an $11.26 exercise price.

When do the NTLA options vest?

The options vest 33% on October 26, 2027, and the remaining 67% in 24 substantially equal monthly installments thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/28/2026 - 04:07 PM EDT Accepted by SEC EDGAR 10/28/2026 - 04:06 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Marantz Jing L.

(Last) (First) (Middle)

C/O INTELLIA THERAPEUTICS, INC.

400 TECHNOLOGY SQUARE, SUITE 100

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	10/26/2026		A		199,822	A	$0.00	199,822	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$11.26	10/26/2026		A		275,061		(2)	10/25/2036	Common Stock	275,061	$0	275,061	D

Explanation of Responses:

1. Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

2. This option was granted on October 26, 2026 with respect to shares of Common Stock, with 33% vesting on October 26, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

	/s/ James Basta, attorney-in-fact	10/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)